| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5814996 | Neuropharmacology | 2013 | 12 Pages |
Abstract
⺠We discuss group III mGluRs as targets in the treatment of Parkinson's disease (PD). ⺠We present recent improvements of group III mGluR agonists and positive modulators. ⺠We review the symptomatic effects of group III mGluR agonists. ⺠We discuss the effect of LSP1-2111 in PD l-DOPA induced dyskinesia. ⺠We discuss the neuroprotective effect of group III mGluR activation on DA neurons.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
M. Amalric, S. Lopez, C. Goudet, G. Fisone, G. Battaglia, F. Nicoletti, J.-P. Pin, F.C. Acher,